[Federal Register Volume 74, Number 119 (Tuesday, June 23, 2009)]
[Notices]
[Pages 29719-29720]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-14705]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 22, 2009, Noramco Inc., 
Division of Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, GA 30601, 
made application by letter to the Drug Enforcement Administration (DEA) 
for registration as a bulk manufacturer of Tapentadol

[[Page 29720]]

(9780), a basic class of controlled substance listed in schedule II.
    The company plans to bulk manufacture the above listed controlled 
substance for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA 22152; and must be filed no later 
than August 24, 2009.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-14705 Filed 6-22-09; 8:45 am]
BILLING CODE 4410-09-P